Search

Your search keyword '"Camu, William"' showing total 546 results

Search Constraints

Start Over You searched for: Author "Camu, William" Remove constraint Author: "Camu, William"
546 results on '"Camu, William"'

Search Results

1. Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

3. Author Correction: The SOD1-mediated ALS phenotype shows a decoupling between age of symptom onset and disease duration

4. Genome-wide structural variant analysis identifies risk loci for non-Alzheimer’s dementias

6. Pharmacometabolomics applied to low‐dose interleukin‐2 treatment in amyotrophic lateral sclerosis

7. The Hexokinase 1 5′-UTR Mutation in Charcot–Marie–Tooth 4G Disease Alters Hexokinase 1 Binding to Voltage-Dependent Anion Channel-1 and Leads to Dysfunctional Mitochondrial Calcium Buffering

9. The SOD1-mediated ALS phenotype shows a decoupling between age of symptom onset and disease duration

10. Cramp–Fasciculation Syndrome Associated with Natural and Added Chemicals in Popular Food Items.

11. Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial

19. Deleterious mutations in the essential mRNA metabolism factor, hGle1, in amyotrophic lateral sclerosis

22. Genome-wide structural variant analysis identifies risk loci for non-Alzheimer’s dementias

23. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis.

24. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis.

25. Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial

26. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

27. Genome-wide Analyses Identify KIF5A as a Novel ALS Gene

29. Serum neurofilament light chain cut‐off definition for clinical diagnosis and prognosis of amyotrophic lateral sclerosis.

30. Genetic screening of ANXA11 revealed novel mutations linked to amyotrophic lateral sclerosis

33. Long-Term Effectiveness, Safety and Tolerability of Fingolimod in Patients with Multiple Sclerosis in Real-World Treatment Settings in France: The VIRGILE Study

42. The HFE p.H63D (p.His63Asp) Polymorphism Is a Modifier of ALS Outcome in Italian and French Patients with SOD1 Mutations

43. Clinical trials in pediatric ALS: a TRICALS feasibility study

44. SLITRK2, an X-linked modifier of the age at onset in C9orf72 frontotemporal lobar degeneration

47. High rate of hypomorphic variants as the cause of inherited ataxia and related diseases: study of a cohort of 366 families

49. Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial

50. Reversible sub-acute motor neuron syndrome after mushroom intoxication masquerading as amyotrophic lateral sclerosis.

Catalog

Books, media, physical & digital resources